Recent News

• 03.25.2025 - PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis
• 03.25.2025 - PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis
• 03.25.2025 - Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
• 03.25.2025 - Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
• 03.24.2025 - Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
• 03.24.2025 - Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
• 02.18.2025 - Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
• 02.18.2025 - Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Recent Filings

• 03.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.06.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - EFFECT Notice of Effectiveness